Short description
Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.
Description
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
Last funding
Cannot Access
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Oxford, Oxfordshire, United Kingdom, Europe
Founded on
October 1, 2018
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Investors
Nopepepe, Nopepepe, No Way, Absolutely Noaccess, Blurry Noaccess, Absolutely Noaccess
Sign in for full access
Founders
Houman Ashrafian, Jeff Rathmell, Jonathan Powell, Luke O'Neill, Michael Rosenblum, Paul-Peter Tak